Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)
Molecular Methods in the Etiological Diagnostics of Acute Central Nervous System Infections: Lymphocytic Herpesviruses and PCR
1 other identifier
observational
60
1 country
1
Brief Summary
Enterovirus and herpes simplex viruses 1 and 2 are the main causative agents of central nervous system infections. Instead, the role of lymphocytic herpesviruses in the etiology of central nervous system (CNS) infections is not clear, even if there is the positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR)-result for the virus. The aim of this study is to evaluate the presence of DNA from lymphocytic herpesviruses in the CSF obtained from the immunocompetent patients with CSF pleocytosis and from the patients with normal CSF leukocyte count.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2011
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2011
CompletedFirst Posted
Study publicly available on registry
September 22, 2011
CompletedStudy Start
First participant enrolled
October 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedSeptember 22, 2011
September 1, 2011
2 years
September 20, 2011
September 21, 2011
Conditions
Keywords
Study Arms (2)
pleocytosis group
40 patients with clinical signs of CNS infection and having CSF pleocytosis.
non-pleocytosis group
20 patients not having CNS infection clinically and not having CSF pleocytosis.
Eligibility Criteria
Residents of the district of Paijat-Hame (200 000 inhabitants).
You may qualify if:
- Immunocompetent patients with clinical symptoms and signs of central nervous system infections and CSF pleocytosis (pleocytosis group)
- Immunocompetent patients without suspicion of CNS infection and no CSF pleocytosis (non-pleocytosis group)
You may not qualify if:
- Suspicion of CNS-infection, eg. encephalitis, but no CSF leukocytosis (pleocytosis group)
- Patients without symptoms of CNS infection, but who has CSF pleocytosis of unknown origin (non-pleocytosis group)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- PaijatHame Central Hospitallead
- University of Turkucollaborator
Study Sites (1)
PaijatHame Central Hospital
Lahti, 15850, Finland
Biospecimen
CSF white cells + CSF supernatant, Blood white cells and serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laura MA Kupila
PaijatHame Central Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Specialist in neurology, MD PhD
Study Record Dates
First Submitted
September 20, 2011
First Posted
September 22, 2011
Study Start
October 1, 2011
Primary Completion
October 1, 2013
Study Completion
December 1, 2013
Last Updated
September 22, 2011
Record last verified: 2011-09